Clinical trials: sponsored by Genmab
Cutaneous T-Cell Lymphoma
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
The purpose of this trial is to determine the effect of HuMax-CD4 as a treatment for early stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00071071
- Testing
- HuMax-CD4
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genmab
Rheumatoid Arthritis
Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker
The purpose of this study is to determine whether HuMax-CD4 is effective in the treatment of active RA in participants who have failed treatment with MTX and at least one TNF-alpha blocking agent.
- Trial name
- NCT00042406
- Testing
- HuMax-CD4
- Where
- 54 sites in United States, Canada
- Volunteers
- 83 people
- Sponsor
- Genmab
Cutaneous T-Cell Lymphoma
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
The purpose of this trial is to determine the effect of HuMax-CD4, as a treatment for advanced stage (late stage) cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00071084
- Testing
- HuMax-CD4
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 22 people
- Sponsor
- Genmab
Solid Tumor
A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies
- Trial name
- innovaTV 206 (NCT03913741)
- Testing
- tisotumab vedotin
- Where
- 8 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Genmab
Head and Neck Cancer, Squamous Cell Cancer
Zalutumumab in Patients With Non-curable Head and Neck Cancer
The purpose of this study is to investigate if zalutumumab in combination with Best Supportive Care (BSC) is superior to BSC in non-curable patients with head and neck cancer
- Trial name
- NCT00382031
- Testing
- Zalutumumab, Control
- Where
- 82 sites in Belgium, Brazil and 10 more
- Volunteers
- 286 people
- Sponsor
- Genmab
Head and Neck Cancer, Squamous Cell Cancer
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer
- Trial name
- NCT00401401
- Testing
- zalutumumab, cisplatin, Radiotherapy
- Where
- 7 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- Genmab
Non Small Cell Lung Cancer
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer compared to patients treated…
- Trial name
- NCT00460551
- Testing
- Zalutumumab, Induction chemotherapy, Radiotherapy
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 13 people
- Sponsor
- Genmab
Non-small Cell Lung Cancer
Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors
A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients with Non-Small Cell Lung Cancer who have Progressive Disease after Treatment with Tyrosine Kinase Inhibitors.
- Trial name
- NCT01449357
- Testing
- zalutumumab
- Sponsor
- Genmab